Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PLEC | Q15149 | 1/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338474 | 0.81 | KDM4E (0.50) | ALDH1A1SLC40A1L3MBTL1CCR1CCR8 | |
| SCHEMBL11429773 | 0.81 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2MAPTPLEC | |
| SCHEMBL29089214 | 0.81 | ALDH1A1 (0.54) | ALDH1A1LMNASMN1; SMN2MAPTPLEC | |
| SCHEMBL30605381 | 0.81 | ALDH1A1 (0.54) | ALDH1A1LMNASMN1; SMN2MAPTPLEC | |
| SCHEMBL68215 | 0.81 | ALDH1A1 (0.54) | ALDH1A1LMNASMN1; SMN2MAPTPLEC | |
| SCHEMBL8544466 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNASMN1; SMN2MAPTPLEC | |
| SCHEMBL21816294 | 0.80 | PSMD14 (0.56) | ALDH1A1LMNAMAPTPLECSLC40A1 | |
| SCHEMBL4602037 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNASMN1; SMN2MAPTPLEC | |
| SCHEMBL679992 | 0.78 | KDM4E (0.60) | ALDH1A1LMNAMAPTALOX12L3MBTL1 | |
| SCHEMBL14820315 | 0.78 | MEN1 (0.53) | ALDH1A1LMNASMN1; SMN2MAPTPLEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| CN-107074808-B | Therapeutic compounds as orexin-1 receptor inhibitors | 希四克斯探索有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-3189043-B1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| US-20200270247-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LIMITED | 2020-08-27 | — | — | US | disclosed |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | INDIVIOR INC. | 2017-10-12 | — | — | US | disclosed |
| CN-107074808-A | It is used as the therapeutic compound of the acceptor inhibitor of orexin 1 | 希四克斯探索有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3189043-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4x Discovery Limited (GB) | 2017-07-12 | — | — | EP | disclosed |
| US-20080153883-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007140385-A2 | THIAZOLE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-0085182-B1 | PROCESS FOR THE PREPARATION OF QUINOLINE MONOCARBOXYLIC ACID | BASF Aktiengesellschaft (DE) | 1986-04-23 | — | — | EP | disclosed |
| EP-0085182-A2 | Process for the preparation of quinoline monocarboxylic acid | BASF Aktiengesellschaft (DE) | 1983-08-10 | — | — | EP | disclosed |
| US-4278680-A | Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid | BOEHRINGER MANNHEIM GMBH (DE) | 1981-07-14 | — | — | US | disclosed |
| US-4221815-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-09 | — | — | US | disclosed |
| US-4207341-A | Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid | BOEHRINGER-MANNHEIM GMBH (DE) | 1980-06-10 | — | — | US | disclosed |
| US-4158063-A | Acylamino(alkyl)benzene derivatives and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | ALDH1A1 1458/4885LMNA 3283/4885SMN1; SMN2 2154/4885 |
| US-20200270247-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | ALDH1A1 1458/4885LMNA 3283/4885SMN1; SMN2 2154/4885 |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | ALDH1A1 1458/4885LMNA 3283/4885SMN1; SMN2 2154/4885 |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | ALDH1A1 1458/4885LMNA 3283/4885SMN1; SMN2 2154/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ALDH1A1 914/4885LMNA 1150/4885SMN1; SMN2 2336/4885 |
| US-20080153883-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | ALDH1A1 1654/4885LMNA 3880/4885SMN1; SMN2 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.